Gilead reported 13% third-quarter product sales growth and 3% non-GAAP diluted earnings per share growth. Management increased 2026 product sales guidance by $900 million at the midpoint based on HIV product outperformance and forecast a steeper non-GAAP EPS decline, largely due to acquisitions.
Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.
Gilead's Yeztugo is a promising new HIV prevention drug, but it is unclear if markets outside the US will embrace this form of therapy.
Metric | GILD | ABBV | MRK |
|---|---|---|---|
Price/Earnings (Normalized) | — | 33.02 | 109.00 |
Price/Book Value | 15.89 | — | 8.06 |
Price/Sales | 6.70 | 7.82 | 5.39 |
Price/Cash Flow | 14.09 | 21.97 | 16.40 |
Metric | GILD | ABBV | MRK |
|---|---|---|---|
Quick Ratio | 0.95 | 0.56 | 0.78 |
Current Ratio | 1.38 | 0.87 | 1.35 |
Interest Coverage | −1.78 | 5.20 | 3.33 |
Metric | GILD | ABBV | MRK |
|---|---|---|---|
Return on Assets (Normalized) | −0.60% | 16.61% | 2.53% |
Return on Equity (Normalized) | −1.77% | — | 7.02% |
Return on Invested Capital (Normalized) | 0.51% | 36.97% | 4.79% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|KJd??@% | LOCK|L< | $1T | |||
| Johnson & Johnson JNJ | LOCK|?&m$$R | LOCK|N> | $665B | |||
| AbbVie Inc ABBV | LOCK|vB^G$K | LOCK|<m | $515B | |||
| Roche Holding AG ADR RHHBY | LOCK|$sVY%m^Q | LOCK|@x | $383B | |||
| Merck & Co Inc MRK | LOCK|Zjgm!< | LOCK|Ywn | $362B | |||
| Novartis AG ADR NVS | LOCK|@JF^QQ^ | LOCK|MP | $308B | |||
| AstraZeneca PLC AZN | LOCK|GD>w>Zk | LOCK|v! | $291B | |||
| Amgen Inc AMGN | LOCK|>$@<>#B | LOCK|syf | $249B | |||
| Novo Nordisk AS ADR NVO | LOCK|VZ>JzL | LOCK|%@Y | $178B |
United States